Content
All Posts > Content under Pharma/Biotech
Market Briefing For Wednesday, March 11
Article By:
Gene Inger
Read
Wednesday, March 11, 2020 4:20 AM EDT
Hurried interventions to stem-the-outflow weren't refined, but sprung on officials by the President, and though they are understaffed by smart people (including in the healthcare realm), this was welcomed of course.
Opening Day: Passage Goes Public Amid Coronavirus-Related Stock Market Meltdown
Biotech Movers On A Roller Coaster Week As Coronavirus Speculation Ramps Up
Article By:
Rod Raynovich
Read
Sunday, March 8, 2020 11:46 AM EDT
Today was a good day to nibble on positions and check your portfolio for needed re-balancing. As you know by now all major indices soared with the NASDAQ up 8.11% to 7418
Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To Two Bi-Specifics
Article By:
ChinaBio® Today
Read
Saturday, March 7, 2020 1:24 PM EDT
Abpro Bio, a Korean company, announced a $1.1 billion agreement to acquire Asian rights (including China) to two bispecific antibody candidates being developed by Abpro of Boston.
Innovation Drives Biotech Stocks-time To Nibble For Longer Term
Article By:
Rod Raynovich
Read
Monday, March 2, 2020 3:13 PM EDT
Biotech and Life Science stocks showed some green on Friday and some themes emerged that are positive were it not for the fear factor and undercurrent of U.S. politics confusing the real situation.
In this article: VIR, BMY, NVS, TMO, RHHBY, ALNY, BMRN, IBB, ILMN, INCY, REGN, GILD, QGEN, XBI, MRNA, ABBV, EDIT, NTLA, CRSP, GH, VCYT, CODX, MO
Week In Review: CICC Capital Closes $229 Million China Fund For Biologics
Article By:
ChinaBio® Today
Read
Saturday, February 29, 2020 1:50 PM EDT
CICC Capital closed a $229 million investment fund for biologics, with investments coming mainly from Chinese organizations inside and outside the biopharma industry. Some of the money will go to companies making COVID-19 vaccines and therapies.
The Bull Will Run Again, It Isn’t A Matter Of “If” But “When”
Article By:
Michael J. Kramer
Read
Saturday, February 29, 2020 12:27 PM EDT
Companies like Apple, Microsoft, Visa, Mastercard, and Tesla, which are all some of my largest holding by weightings, may see struggles in the short-term, six months or so, but are likely to rebound over the longer-term.
Exclusive Interview With Lindsay Rosenwald, CEO Of Fortress Biotech
Article By:
Terry Chrisomalis
Read
Thursday, February 27, 2020 5:57 AM EDT
I recently had the opportunity to interview Lindsay A. Rosenwald, CEO of Fortress Biotech, Inc. (FBIO), an innovative biopharmaceutical company.
CollPlant Technologies - New All-Time High
Article By:
Jim Van Meerten
Read
Tuesday, February 25, 2020 4:22 PM EDT
Revenue expected to grow 87.90% this year and another 131.70% next year.
In this article: CLGN